194 related articles for article (PubMed ID: 32890079)
1. Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study.
Sahdev I; Brochstein J; Werther N; Stiles J
J Pediatr Hematol Oncol; 2020 Nov; 42(8):e718-e722. PubMed ID: 32890079
[TBL] [Abstract][Full Text] [Related]
2. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
Kharbanda S; Smith AR; Hutchinson SK; McKenna DH; Ball JB; Lamb LS; Agarwal R; Weinberg KI; Wagner JE
Biol Blood Marrow Transplant; 2014 Apr; 20(4):581-6. PubMed ID: 24370862
[TBL] [Abstract][Full Text] [Related]
3. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
Patel K; Parmar S; Shah S; Shore T; Gergis U; Mayer S; van Besien K
Biol Blood Marrow Transplant; 2016 Mar; 22(3):456-61. PubMed ID: 26524732
[TBL] [Abstract][Full Text] [Related]
5. Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
Abraham A; Cluster A; Jacobsohn D; Delgado D; Hulbert ML; Kukadiya D; Murray L; Shenoy S
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1587-1592. PubMed ID: 28578010
[TBL] [Abstract][Full Text] [Related]
6. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
[TBL] [Abstract][Full Text] [Related]
7. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Chakraverty R; Peggs K; Chopra R; Milligan DW; Kottaridis PD; Verfuerth S; Geary J; Thuraisundaram D; Branson K; Chakrabarti S; Mahendra P; Craddock C; Parker A; Hunter A; Hale G; Waldmann H; Williams CD; Yong K; Linch DC; Goldstone AH; Mackinnon S
Blood; 2002 Feb; 99(3):1071-8. PubMed ID: 11807015
[TBL] [Abstract][Full Text] [Related]
8. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
Mead AJ; Thomson KJ; Morris EC; Mohamedbhai S; Denovan S; Orti G; Fielding AK; Kottaridis PD; Hough R; Chakraverty R; Linch DC; Mackinnon S; Peggs KS
Blood; 2010 Jun; 115(25):5147-53. PubMed ID: 20371745
[TBL] [Abstract][Full Text] [Related]
9. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Pérez-Simón JA; Kottaridis PD; Martino R; Craddock C; Caballero D; Chopra R; García-Conde J; Milligan DW; Schey S; Urbano-Ispizua A; Parker A; Leon A; Yong K; Sureda A; Hunter A; Sierra J; Goldstone AH; Linch DC; San Miguel JF; Mackinnon S;
Blood; 2002 Nov; 100(9):3121-7. PubMed ID: 12384408
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.
Marsh RA; Lane A; Mehta PA; Neumeier L; Jodele S; Davies SM; Filipovich AH
Blood; 2016 Jan; 127(4):503-12. PubMed ID: 26644451
[TBL] [Abstract][Full Text] [Related]
11. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
Marsh JC; Gupta V; Lim Z; Ho AY; Ireland RM; Hayden J; Potter V; Koh MB; Islam MS; Russell N; Marks DI; Mufti GJ; Pagliuca A
Blood; 2011 Aug; 118(8):2351-7. PubMed ID: 21518925
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
[TBL] [Abstract][Full Text] [Related]
14. A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease.
Khandelwal P; Bleesing JJ; Davies SM; Marsh RA
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2011-2018. PubMed ID: 27543157
[TBL] [Abstract][Full Text] [Related]
15. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.
Bhatia M; Jin Z; Baker C; Geyer MB; Radhakrishnan K; Morris E; Satwani P; George D; Garvin J; Del Toro G; Zuckerman W; Lee MT; Licursi M; Hawks R; Smilow E; Baxter-Lowe LA; Schwartz J; Cairo MS
Bone Marrow Transplant; 2014 Jul; 49(7):913-20. PubMed ID: 24797180
[TBL] [Abstract][Full Text] [Related]
16. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
Rzepecki P; Sarosiek T; Szczylik C
Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
[TBL] [Abstract][Full Text] [Related]
18. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
Abdel-Azim H; Mahadeo KM; Zhao Q; Khazal S; Kohn DB; Crooks GM; Shah AJ; Kapoor N
Am J Hematol; 2015 Nov; 90(11):1021-6. PubMed ID: 26242764
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
Slatter MA; Rao K; Abd Hamid IJ; Nademi Z; Chiesa R; Elfeky R; Pearce MS; Amrolia P; Worth A; Flood T; Abinun M; Hambleton S; Qasim W; Gaspar HB; Cant AJ; Gennery AR; Veys P
Biol Blood Marrow Transplant; 2018 Mar; 24(3):529-536. PubMed ID: 29155317
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.
Bhoopalan SV; Cross SJ; Panetta JC; Triplett BM
Cancer Chemother Pharmacol; 2020 Dec; 86(6):711-717. PubMed ID: 33037919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
